Vaccine stimulates multi-pronged immune attack, inhibits tumor-induced immune suppression
Scientists are using their increasing knowledge of the complex interaction between cancer and the immune system to engineer increasingly potent anti-cancer vaccines. Now researchers at the National Institute of Biomedical Imaging and Bioengineering (NIBIB) have developed a synergistic nanovaccine packing DNA and RNA sequences that modulate the immune response, along with anti-tumor antigens, into one small nanoparticle. The nanovaccine produced an immune response that specifically killed tumor tissue, while simultaneously inhibiting tumor-induced immune suppression. Together this blocked lung tumor growth in a mouse model of metastatic colon cancer.
The molecular dance between cancer and the immune system is a complex one and scientists continue to identify the specific molecular pathways that rev up or tamp down the immune system. Biomedical engineers are using this knowledge to create nanoparticles that can carry different molecular agents that target these pathways. The goal is to simultaneously stimulate the immune system to specifically attack the tumor while also inhibiting the suppression of the immune system, which often occurs in cancer patients. The aim is to press on the gas pedal of the immune system while also releasing the emergency brake.
A key hurdle is to design a system to reproducibly and efficiently create a nanoparticle loaded with multiple agents that synergize to mount an enhanced immune attack on the tumor. Engineers at the NIBIB report the development and testing of such a nanovaccine in the November issue of Nature Communications.1
Making all the parts fit
Guizhi Zhu, Ph.D., a post-doctoral fellow in the NIBIB Laboratory of Molecular Imaging and Nanomedicine (LOMIN) and lead author on the study, explains the challenge. “We are very excited about putting multiple cooperating molecules that have anti-cancer activity into one nanovaccine to increase effectiveness. However, the bioengineering challenge is fitting everything in to a small particle and designing a way to maintain its structural integrity and biological activity.”
Zhu and his colleagues have created what they call a “self-assembling, intertwining DNA-RNA nanocapsule loaded with tumor neoantigens.” They describe it as a synergistic vaccine because the components work together to stimulate and enhance an immune attack against a tumor.
In addition to engineering a system where the DNA, RNA and tumor neoantigens self-assemble into a stable nanoparticle, an important final step in the process is shrinking the particle. Zhu explains: “Shrinking the particle is a critical step for activating an immune response. This is because a very small nanoparticlecan more readily move through the lymphatic vessels to reach the parts of the immune system such as lymph nodes. A process that is essential for immune activation.”
The method for shrinking also had to be engineered. This was achieved by coating the particle with a positively charged polypeptide that interacts with the negatively charged DNA and RNA components to condense it to one-tenth of its original size.
Testing the vaccine
The nanovaccine was injected under the skin of the mice 10, 16, and 22 days after the colon cancer cells were injected. To compare to the nanovaccine, two control groups of mice were analyzed; one group was injected with just the DNA and the neoantigen in solution but not formed into a nanovaccine particle, and the second control group was injected with an inert buffer solution.
At 40 days into the experiment, lung tumors from the nanovaccine-treated and the control groups were assessed by PET-CT imaging, and then removed and weighed. In mice treated with the nanovaccine, tumors were consistently one tenth the size of the tumors that were found in mice in both control groups.
Further testing revealed that mice receiving the nanovaccine had a significant increase in circulating cytotoxic T lymphocytes (CTLs) that specifically targeted the neoantigen on the colon cancer cells. CTLs are cells that attack and kill virus-infected cells and those damaged in other ways, such as cancerous cells.
An important aspect of the nanovaccine approach is that it mounts an anti-tumor immune response that circulates through the system, and therefore is particularly valuable for finding and inhibiting metastatic tumors growing throughout the body.
The researchers view their nanovaccine as an important part of eventual therapies combining immunotherapy with other cancer killing approaches.
The Latest on: Nanovaccine
- Bio & Medicine newson January 23, 2020 at 4:00 pm
An interdisciplinary team from the University of Basel in Switzerland has succeeded in creating a direct path for artificial nanocontainers to enter into the nucleus of living cells. To this end ...
- New nanovaccine for deadly skin canceron August 6, 2019 at 5:36 am
In a counterattack, scientists in the Satchi-Fainaro laboratory at Tel Aviv University worked on a combination of therapies, namely, a novel nanovaccine with anti-PD-1 antibody (αPD-1).
- Nanovaccine design can dramatically improve cancer immunotherapieson May 6, 2019 at 12:44 pm
(Nanowerk News) When it comes to the effectiveness of nanotherapeutic vaccines, shape matters. A Northwestern University team investigated a set of spherical nucleic acids (SNAs) for their potential ...
- Nanovaccine Boosts Metabolic Syndrome Immunityon March 30, 2019 at 12:58 pm
In mice with metabolic disorders, nanovaccine developed by Cornell researchers was found to boost immunity. Metabolic disorders are linked to gut bacteria - a population that shows resistance to ...
- Efficacy of mucosal polyanhydride nanovaccine against respiratory syncytial virus infection in the neonatal calfon February 13, 2018 at 4:00 pm
Here, we developed a novel, mucosal nanovaccine that encapsulates the post-fusion F and G glycoproteins from BRSV into polyanhydride nanoparticles and determined the efficacy of the vaccine ...
- Engineers use natural protein as nanoshuttle for anti-cancer vaccineson February 6, 2018 at 4:00 pm
The use of natural albumin as a universal vaccine shuttle is a significant step towards the application of cancer nanovaccine immunotherapy in humans. Nanovaccines that work to mount an immune ...
- DNA Ferrying Nanoparticles Turbocharge Cancer Immunotherapyon August 25, 2016 at 1:01 pm
At the National Institute of Biomedical Imaging and Bioengineering (NIBIB), a part of the National Institutes of Health, scientists have developed a “nanovaccine” for safer delivery of ...
- Nanovaccine to boost poultry immunityon February 1, 2016 at 11:02 pm
CHENNAI: Newcastle disease is one of the most common contagious diseases that affect poultry birds with a mortality rate as high as 90%. It often gets transmitted to workers who handle infected ...
- No-refrigeration, spray nano-vaccine could curb diseases in remote areason March 18, 2014 at 5:00 pm
“Our nanovaccine approach could be instrumental for containing future outbreaks of recently emerged and re-emerging diseases, such as SARS, new flu strains and multi-drug resistant tuberculosis,” said ...
- Vaccines to save Qld cattle industry millionson July 18, 2012 at 8:59 pm
The government has leveraged its previous investment in the nanovaccine research with a $1 million grant to move both projects forward. Other collaborators on the project with QAAFI and government ...
via Google News and Bing News